Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma

Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma. #lymphoma #lymsm https://t.co/aaq2bI6EUw

Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma https://t.co/9VbueCvzkp

Blocking PD-L1 in B cell lymphoma. #lymsm @lymphomahub DOI https://t.co/pZOlVBHCoe https://t.co/d3Mftm1ty2